ProCE Banner Activity

Attack of the Finicky Foe: Updates on Carbapenem-Resistant Acinetobacter baumannii Treatment

Clinical Thought

Read my commentary on the latest data related to the treatment of CRAB infections, including IDSA guidance updates and the potential role of sulbactam/durlobactam based on findings from the ATTACK trial.

Released: August 08, 2023

Share

Faculty

Emily Heil

Emily Heil, PharmD, MS, BCIDP, AAHIVP

Associate Professor
Department of Practice, Sciences, and Health Outcomes Research
University of Maryland School of Pharmacy
Infectious Diseases Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Merck & Co., Inc.

Disclosure

Primary Author

Emily Heil, PharmD, MS, BCIDP, AAHIVP

Associate Professor
Department of Practice, Sciences, and Health Outcomes Research
University of Maryland School of Pharmacy
Infectious Diseases Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland

Emily Heil, PharmD, MS, BCIDP, AAHIVP, has no relevant financial relationships to disclose.